PH-DyPred: A Multimodal Dynamic Risk Prediction Study in Pulmonary Hypertension

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFirst Affiliated Hospital of Fujian Medical University

About this trial

Pulmonary hypertension (PH) is a progressive cardiopulmonary disease characterized by elevated pulmonary artery pressure and vascular remodeling, which leads to right heart failure and increased mortality. Despite advances in diagnostics, risk stratification remains limited due to the disease's heterogeneity. This study aims to develop and validate a dynamic risk prediction model for PH by integrating multimodal data-including echocardiography, Cardiac MRI, PET-MR, ECG, biomarkers, and clinical features-using advanced machine learning algorithms. The study will establish a prospective cohort of PH patients to explore predictive markers, stratify prognosis, and provide a scientific basis for early warning and individualized management.

Eligibility criteria

Qualifiers

Adults aged 18 years or older

Pulmonary artery systolic pressure (PASP) ≥35 mmHg as estimated by echocardiography

Provided written informed consent

Disqualifiers

Severe hepatic or renal insufficiency

Malignancy under active treatment

Severe infection

Active autoimmune disease

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

1,000 Participants
are grouped into 1 trial group